How to take Binimetinib

Before patients start taking binimetinib, doctors will confirm the presence of BRAF V600E or V600K mutations in tumor specimens (melanoma or non-small cell lung cancer) and then test the tumor tissue if no mutations are detected in plasma specimens. Bimetinib tablets for oral use contain 15 mg of binimetinib and are only available by prescription.

The recommended dose of bimetinib is 45 mg orally administered twice daily, approximately 12 hours apart, in combination with encorafenib until disease progression or unacceptable toxicity. Can be taken with or without food. Refer to the prescribing information for recommended doses of canafenib. If the patient experiences adverse reactions while using bimetinib, the doctor will adjust the dose of the drug according to the severity of the condition. The initial dose can be reduced to 30 mg orally twice a day. If the patient cannot tolerate 30 mg twice a day, the drug will be permanently discontinued. For patients with moderate (total bilirubin levels greater than 1.5 and ≤3 × ULN and any AST) or severe (total bilirubin levels >3 × ULN and any AST) hepatic impairment, the recommended dose is 30 mg orally twice daily.

The original drug bimetinib has not yet been launched in China, and therefore is not covered by medical insurance. Bimetiniboriginal drug sold overseas, specifications15mg*84 tablets may cost more than 10,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic drug of Bimetinib produced and launched. For more drug information and specific prices, please consult a medical consultant.